Axim Biotechnologies Inc (AXIM)

[Blue Skys]

When JH mails the investor letter that was promised to be sent late August 2023 and/or updates the AS on OTC markets to match the AS on the Nevada SOS website and provides detail of the OS increase investors will have a picture that they can analyze. Will that detail be provided in the pending 10K or will it only be partially disclosed with just the AS increase, with the note conversion still behind the veil of the Derivative Liability Insufficient Shares entry? It's impossible to analyze the financial statements even if there was a revenue forecast since the OS as disclosed is effectively unknown. It is true that the company has a pipeline that seems to have made its way to the faucet but it also seems that a great deal of effort has been made to conceal the effective share count and convertible note status by using perfectly legal FASB approved accounting practices.

The March 9 update on OTC markets is puzzling because the Transfer Agent showed an increase in the OS but did not account for the AS increase and it is not clear at least to me what constituted the 38,280,000 OS increase. Was that dilution for cash, shares for the companies partners, variable note conversions (partial)? In a period of minimal OS disclosure there must have been an event related to the OS that the company felt needed to be disclosed to persuade them to post it to OTC Markets.

Authorized Shares
300,000,000 03/09/2024
Outstanding Shares
275,929,403 03/09/2024
Restricted
157,711,651 03/09/2024
Unrestricted
118,217,752 03/09/2024